换一批
换一批Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission.
作者：
主题词
成年人(Adult);核心结合因子类(Core Binding Factors);造血干细胞移植(Hematopoietic Stem Cell Transplantation);人类(Humans);白血病, 髓样, 急性(Leukemia, Myeloid, Acute);突变(Mutation);肌球蛋白重链(Myosin Heavy Chains);肿瘤, 残余(Neoplasm, Residual);预后(Prognosis);复发(Recurrence);回顾性研究(Retrospective Studies);fms样酪氨酸激酶3(fms-Like Tyrosine Kinase 3)
DOI
10.1002/hon.3015
PMID
35531760
发布时间
2022-10-13
- 浏览2
Hematological oncology
724-733页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
